Annual Retained Earnings
-$7.01 B
-$440.24 M-6.70%
31 December 2023
Summary:
Alnylam Pharmaceuticals annual retained earnings is currently -$7.01 billion, with the most recent change of -$440.24 million (-6.70%) on 31 December 2023. During the last 3 years, it has fallen by -$2.42 billion (-52.87%). ALNY annual retained earnings is now -156189.65% below its all-time high of -$4.49 million, reached on 31 December 2002.ALNY Retained Earnings Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Retained Earnings
-$7.20 B
-$111.57 M-1.57%
30 September 2024
Summary:
Alnylam Pharmaceuticals quarterly retained earnings is currently -$7.20 billion, with the most recent change of -$111.57 million (-1.57%) on 30 September 2024. Over the past year, it has dropped by -$332.26 million (-4.84%). ALNY quarterly retained earnings is now -24305.40% below its all-time high of -$29.52 million, reached on 31 December 2003.ALNY Quarterly Retained Earnings Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ALNY Retained Earnings Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -6.7% | -4.8% |
| 3 y3 years | -52.9% | -39.1% |
| 5 y5 years | -146.7% | -108.8% |
ALNY Retained Earnings High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -52.9% | at low | -39.1% | at low |
| 5 y | 5 years | -146.7% | at low | -108.8% | at low |
| alltime | all time | <-9999.0% | at low | <-9999.0% | at low |
Alnylam Pharmaceuticals Retained Earnings History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | -$7.20 B(+1.6%) |
| June 2024 | - | -$7.09 B(+0.2%) |
| Mar 2024 | - | -$7.08 B(+0.9%) |
| Dec 2023 | -$7.01 B(+6.7%) | -$7.01 B(+2.0%) |
| Sept 2023 | - | -$6.87 B(-2.1%) |
| June 2023 | - | -$7.02 B(+4.1%) |
| Mar 2023 | - | -$6.74 B(+2.7%) |
| Dec 2022 | -$6.57 B(+20.8%) | -$6.57 B(+3.3%) |
| Sept 2022 | - | -$6.36 B(+6.8%) |
| June 2022 | - | -$5.96 B(+4.9%) |
| Mar 2022 | - | -$5.68 B(+4.4%) |
| Dec 2021 | -$5.44 B(+18.6%) | -$5.44 B(+5.0%) |
| Sept 2021 | - | -$5.18 B(+4.1%) |
| June 2021 | - | -$4.98 B(+4.0%) |
| Mar 2021 | - | -$4.79 B(+4.4%) |
| Dec 2020 | -$4.59 B(+23.0%) | -$4.59 B(+5.6%) |
| Sept 2020 | - | -$4.34 B(+6.2%) |
| June 2020 | - | -$4.09 B(+4.6%) |
| Mar 2020 | - | -$3.91 B(+4.9%) |
| Dec 2019 | -$3.73 B(+31.2%) | -$3.73 B(+8.0%) |
| Sept 2019 | - | -$3.45 B(+6.4%) |
| June 2019 | - | -$3.24 B(+7.3%) |
| Mar 2019 | - | -$3.02 B(+6.4%) |
| Dec 2018 | -$2.84 B(+32.3%) | -$2.84 B(+8.0%) |
| Sept 2018 | - | -$2.63 B(+10.3%) |
| June 2018 | - | -$2.38 B(+7.4%) |
| Mar 2018 | - | -$2.22 B(+3.4%) |
| Dec 2017 | -$2.15 B(+29.6%) | -$2.15 B(+7.1%) |
| Sept 2017 | - | -$2.01 B(+6.5%) |
| June 2017 | - | -$1.88 B(+6.7%) |
| Mar 2017 | - | -$1.76 B(+6.5%) |
| Dec 2016 | -$1.66 B(+32.9%) | -$1.66 B(+7.3%) |
| Sept 2016 | - | -$1.54 B(+7.2%) |
| June 2016 | - | -$1.44 B(+6.7%) |
| Mar 2016 | - | -$1.35 B(+8.3%) |
| Dec 2015 | -$1.25 B(+30.3%) | -$1.25 B(+7.8%) |
| Sept 2015 | - | -$1.16 B(+7.1%) |
| June 2015 | - | -$1.08 B(+7.1%) |
| Mar 2015 | - | -$1.01 B(+5.3%) |
| Dec 2014 | -$956.63 M | -$956.63 M(+2.3%) |
| Sept 2014 | - | -$935.24 M(+4.9%) |
| June 2014 | - | -$891.25 M(+5.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2014 | - | -$847.18 M(+42.1%) |
| Dec 2013 | -$596.24 M(+17.6%) | -$596.24 M(+5.7%) |
| Sept 2013 | - | -$563.88 M(+5.6%) |
| June 2013 | - | -$534.19 M(+3.5%) |
| Mar 2013 | - | -$516.02 M(+1.8%) |
| Dec 2012 | -$507.01 M(+26.4%) | -$507.01 M(+14.0%) |
| Sept 2012 | - | -$444.82 M(+4.6%) |
| June 2012 | - | -$425.32 M(+3.1%) |
| Mar 2012 | - | -$412.36 M(+2.8%) |
| Dec 2011 | -$401.00 M(+16.8%) | -$401.00 M(+3.7%) |
| Sept 2011 | - | -$386.69 M(+3.5%) |
| June 2011 | - | -$373.46 M(+3.8%) |
| Mar 2011 | - | -$359.63 M(+4.7%) |
| Dec 2010 | -$343.35 M(+14.5%) | -$343.35 M(+2.1%) |
| Sept 2010 | - | -$336.42 M(+2.9%) |
| June 2010 | - | -$326.79 M(+4.7%) |
| Mar 2010 | - | -$312.15 M(+4.1%) |
| Dec 2009 | -$299.83 M(+18.9%) | -$299.83 M(+2.7%) |
| Sept 2009 | - | -$292.04 M(+3.3%) |
| June 2009 | - | -$282.83 M(+8.7%) |
| Mar 2009 | - | -$260.13 M(+3.1%) |
| Dec 2008 | -$252.24 M(+11.6%) | -$252.24 M(+3.9%) |
| Sept 2008 | - | -$242.85 M(+1.2%) |
| June 2008 | - | -$239.99 M(+5.6%) |
| Mar 2008 | - | -$227.23 M(+0.5%) |
| Dec 2007 | -$225.99 M(+60.8%) | -$225.99 M(-0.7%) |
| Sept 2007 | - | -$227.66 M(+30.2%) |
| June 2007 | - | -$174.86 M(+7.8%) |
| Mar 2007 | - | -$162.17 M(+15.4%) |
| Dec 2006 | -$140.53 M(+32.7%) | -$140.53 M(+6.4%) |
| Sept 2006 | - | -$132.09 M(+5.9%) |
| June 2006 | - | -$124.69 M(+8.6%) |
| Mar 2006 | - | -$114.78 M(+8.4%) |
| Dec 2005 | -$105.92 M(+68.1%) | -$105.92 M(+15.8%) |
| Sept 2005 | - | -$91.43 M(+13.2%) |
| June 2005 | - | -$80.75 M(+16.0%) |
| Mar 2005 | - | -$69.60 M(+10.5%) |
| Dec 2004 | -$63.01 M(+113.4%) | -$63.01 M(+9.9%) |
| Sept 2004 | - | -$57.30 M(+12.6%) |
| June 2004 | - | -$50.89 M(+15.8%) |
| Mar 2004 | - | -$43.93 M(+48.8%) |
| Dec 2003 | -$29.52 M(+558.1%) | -$29.52 M |
| Dec 2002 | -$4.49 M | - |
FAQ
- What is Alnylam Pharmaceuticals annual retained earnings?
- What is the all time high annual retained earnings for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals annual retained earnings year-on-year change?
- What is Alnylam Pharmaceuticals quarterly retained earnings?
- What is the all time high quarterly retained earnings for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals quarterly retained earnings year-on-year change?
What is Alnylam Pharmaceuticals annual retained earnings?
The current annual retained earnings of ALNY is -$7.01 B
What is the all time high annual retained earnings for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high annual retained earnings is -$4.49 M
What is Alnylam Pharmaceuticals annual retained earnings year-on-year change?
Over the past year, ALNY annual retained earnings has changed by -$440.24 M (-6.70%)
What is Alnylam Pharmaceuticals quarterly retained earnings?
The current quarterly retained earnings of ALNY is -$7.20 B
What is the all time high quarterly retained earnings for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high quarterly retained earnings is -$29.52 M
What is Alnylam Pharmaceuticals quarterly retained earnings year-on-year change?
Over the past year, ALNY quarterly retained earnings has changed by -$332.26 M (-4.84%)